CompletedNot Applicable

COVID-19 Vaccine and Ovarian Reserve

Israel200 participantsStarted 2021-02-01

Plain-language summary

As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .

Who can participate

Age range11 Years – 42 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 11-42 * No previous exposure to Covid-19 vaccine (first or second dose) * No known past Covid-19 infection Exclusion Criteria: * Premature ovarian failure * Pregnancy * Fertility treatment * Past Covid-19 infection

What they're measuring

Delta in AMH levels

Timeframe: From first vaccination until the second AMH sampling - after three month

Trial details

NCT IDNCT04748172

SponsorSheba Medical Center

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2023-06-01

View on ClinicalTrials.gov More Fertility Issues trials